» Articles » PMID: 37161608

Better Resolving of Anti-CD38 Antibody Interference with Blood Compatibility Testing by Using Manual Polybrene Method compared with Dithiothreitol-pretreatment Indirect Antiglobulin Test

Overview
Journal J Clin Lab Anal
Publisher Wiley
Date 2023 May 10
PMID 37161608
Authors
Affiliations
Soon will be listed here.
Abstract

Background: It is advised to pretreat the reagent erythrocytes with Dithiothreitol (DTT) to denature the surface CD38 to prevent anti-CD38 monoclonal antibodies (MoAb) from interfering with the blood compatibility test. Anti-CD38 has little impact on the Polybrene test, but it is still unknown how sensitive it is to detect irregular antibodies and how effective it is when compared to the standard DTT-based method.

Methods: Twenty-one patients receiving daratumumab (N = 13) and isatuximab (N = 8) had their serum collected. Standard anti-sera (anti-c, D, E, Fy , Jk , M, Mi ) with serial dilution were added to patients' serum. Antibody screening tests were performed simultaneously using the manual polybrene method (MP) and DTT-pretreated, automatic indirect antiglobulin test (DTT-IAT) to compare the detection sensitivity. These two methods' operating times and costs were also analyzed.

Results: Both MP and DTT-IAT can overcome the interference caused by anti-CD38 MoAb. However, MP is more sensitive in detecting anti-M and anti-Mi and is comparable to DTT-IAT in detecting other antibodies. In terms of cost and operating time, MP is also far superior to DTT-IAT.

Conclusion: MP is a cost-effective alternative to DTT-IAT in resolving anti-CD38 interference and is especially suitable for populations with a high prevalence of anti-M and anti-Mi . However, both methods have a well-known drawback of low detection sensitivity for anti-K, and K-units should be provided to patients to prevent hemolytic transfusion reactions.

Citing Articles

Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma.

Wijnands C, Karel P, Gloerich J, Armony G, Tzasta A, de Kat Angelino C Pharmaceutics. 2025; 17(1).

PMID: 39861781 PMC: 11769374. DOI: 10.3390/pharmaceutics17010135.


Better resolving of anti-CD38 antibody interference with blood compatibility testing by using manual polybrene method compared with dithiothreitol-pretreatment indirect antiglobulin test.

Feng C, Chang C, Lien Z, Lin J, Chen T, Yeh S J Clin Lab Anal. 2023; 37(8):e24891.

PMID: 37161608 PMC: 10290224. DOI: 10.1002/jcla.24891.

References
1.
Yousuf R, Abdul Aziz S, Yusof N, Leong C . Incidence of Red Cell Alloantibody among the Transfusion Recipients of Universiti Kebangsaan Malaysia Medical Centre. Indian J Hematol Blood Transfus. 2014; 29(2):65-70. PMC: 3636363. DOI: 10.1007/s12288-012-0155-x. View

2.
Voorhees P, Kaufman J, Laubach J, Sborov D, Reeves B, Rodriguez C . Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020; 136(8):936-945. PMC: 7441167. DOI: 10.1182/blood.2020005288. View

3.
Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L . Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10192):29-38. DOI: 10.1016/S0140-6736(19)31240-1. View

4.
Lin M, Broadberry R . Immunohematology in Taiwan. Transfus Med Rev. 1998; 12(1):56-72. DOI: 10.1016/s0887-7963(98)80090-4. View

5.
Yeh T, Yeh C, Liu Y, Hsiao H . Manual polybrene method for pretransfusion test could overcome the interference of daratumumab therapy in myeloma. Transfusion. 2019; 59(8):2751-2752. DOI: 10.1111/trf.15341. View